Colistin-daptomycin, colistin-linezolid, colistin-vancomycin combination effects on colistin in multi-resistant acinetobacter baumannii strains

Year 2018, Volume: 5 Issue: 2, 124 - 129, 28.02.2018

Arzu Irvem

https://doi.org/10.17546/msd.391234

Abstract

Objective: The most important problem in the treatment of nosocomial Acinetobacter baumannii (A. baumannii) infections which is increasingly seen in recent years is that almost all strains are resistant to many antibiotics, including carbapenems, and that the extinction of antibiotic options to be used in treatment. This leads the clinicians to new treatment options and suggests the use of combined antibiotics to achieve success in both the treatment of multi-drug-resistant A. baumannii (MDRAB) infections as well as to prevent resistance development. We investigated the in vitro activity of colistin in combination with vancomycin, linezolid or daptomycin against MDRAB to determine whether these combinations would be considered for clinical use. . Methods: The fractional inhibitory concentration (FIC) index was used to determine the antibiotic combination effects and to evaluate the effect of antibiotic combinations on the bacteria. Results: MIC values of colistin/vancomycin, colistin/linezolid, and colistin/daptomycin in 10 strains (33.3%) gave similar results. Twenty strains gave different MIC results according to antibiotics. The colistin/daptomycin antagonistic ratio was high when the colistin/vancomycin synergy ratio was high compared to the others. Conclusion: Antibiotic combinations can be used as an alternative treatment approach in multi-drug resistant A. baumannii infections.

Keywords

Acinetobacter baumannii, Colistin, Combinations’ effect

References

• 1. Falagas ME, Vardakas KZ, Roussos NS. Trimethoprim/sulfamethoxazole for Acinetobacter spp.: a review of current microbiological and clinical evidence, Int J Antimicrob Agents 2015;46 (3):231-241. doi: 10.1016/j.ijantimicag.2015.04.002. Epub 2015 May 15.
• 2. Silhavy TJ, Kahne D, Walker S. The bacterial cell envelope. Cold Spring Harbor Perspect Biol 2010; 2 (5): a000414. doi: 10.1101/cshperspect.a000414. Epub 2010 Apr 14.
• 3. Liu B, Liu Y, DI X, Zhang X, Wang R, Bai Y, Wang J. Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii. Rev. Soc. Bras. Med. Trop2014;47 (4):451-456.
• 4. Roberts SA, Findlay R, Lang SDR. Investigation of an outbreak of multi-drug resistant Acinetobacter baumannii in an intensive care burns unit. J Hosp Infect 2001;48(3):228-232.
• 5. García-Quintanilla M, Pulido MR, LópezRojas R, Pachón J, McConnell MJ. Emerging therapies for multidrug resistant Acinetobacter baumannii, Trends Microbiol 2013;21 (3):157- 163.
• 6. Haddad FA, Horn KV, Carbonaro C, Rosenfeld MA, Wormser GP. Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test. Eur J Clin Microbiol Infect Dis 2005;24 (8):577-579.
• 7. Manchanda V, Sanchaita S, Singh N. Multidrug resistant Acinetobacter, J Glob Infect Dis 2010;2 (3): 291-304.
• 8. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008;32 (1):29- 32.
• 9. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011;11 (11):834-844.
• 10. Vidaillac C, Benichou L, Duval RE. In vitro synergy of Colistin combinations against Colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates, Antimicrob Agent Chemother 2012;56 (9):4856-4861.
• 11. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54 (12):5316-5322.
• 12. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a Vancomycin-Colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother. 2011; 66 (5): 1047-1051.
• 13. Ceccarelli G, Oliva A, D’Ettorre G, D’Abramo A, Caresta E, Barbara CS, Mascellino MT, Papoff P, Moretti C, Vullo V et al. The role of Vancomycin in addition with Colistin and meropenem against Colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit. Advances in Microbiology 2017;1 (7).
• 14. Okasha HAS, Meheissen MA. In Vitro Activity of Colistin and Vancomycin or Azithromycin Combinations on Extensively Drug Resistant Acinetobacter baumannii Clinical Isolates. Advances in Microbiology 2017; 7:71-81
• 15. O’Hara JA, Ambe LA, Casella LG, Townsend BM, Pelletier MR, Ernst RK, Shanks RM, Doi Y. Activities of Vancomycin-containing regimens against Colistin-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother. 2013;57 (5):2103-2108. doi: 10.1128/AAC.02501-12. Epub 2013 Feb 19.
• 16. Boselli E, Breilh D, Caillault-Sergent A, Djabarouti S, Guillaume C, Xuereb F, Bouvet L, Rimmelé T, Saux MC, Allaouchiche B. Alveolar diffusion and pharmacokinetics of Linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J Antimicrob Chemother. 2012;67 (5):1207-1210. doi: 10.1093/jac/dks022. Epub 2012 Feb 20.
• 17. Galani I, Orlandou K, Moraitou H, Petrikkos G, Souli M. Colistin/Daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. International Journal of Antimicrobial Agents 2014; 43 (4); 370-374.
• 18. Phee L, Hornsey M, Wareham DW. In vitro activity of Daptomycin in combination with low-dose Colistin against a diverse collection of Gram-negative bacterial pathogens. Eur J Clin Microbiol Infect Dis.2013; 32 (10):1291-1294.
• 19. Yang H, Chen G, Hu L, Liu Y, Cheng J, Li H, Ye Y, Li J. In vivo activity of Daptomycin/Colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents. 2015;45 (2):188-191.
• 20. Manchanda V, Sanchaita S, Singh N. Multidrug resistant Acinetobacter, J Glob Infect Dis. 2010;2 (3): 291-304.